Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 9/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25565642 | 1.00 | DRD3 (0.51) | DRD3DRD2DRD4 | |
| SCHEMBL9801156 | 1.00 | DRD3 (0.51) | DRD3DRD2DRD4 | |
| SCHEMBL11576109 | 0.89 | DRD3 (0.42) | DRD3DRD2DRD4 | |
| SCHEMBL9935145 | 0.88 | DRD3 (0.47) | DRD3DRD2DRD4 | |
| SCHEMBL9935115 | 0.88 | DRD3 (0.47) | DRD3DRD4 | |
| SCHEMBL10815638 | 0.87 | EBP (0.44) | DRD3DRD2DRD4 | |
| SCHEMBL24508741 | 0.86 | DRD3 (0.46) | DRD3DRD2DRD4 | |
| SCHEMBL16059471 | 0.86 | DRD3 (0.45) | DRD3DRD2DRD4 | |
| SCHEMBL22463761 | 0.85 | EBP (0.47) | DRD3DRD2DRD4 | |
| SCHEMBL5659819 | 0.85 | EBP (0.47) | DRD3DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226196-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF INTERLEUKIN-2-INDUCIBLE T-CELL KINASE AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230158157-A1 | POTENT AND SELECTIVE DEGRADERS OF ALK | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226196-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF INTERLEUKIN-2-INDUCIBLE T-CELL KINASE AND METHODS OF USE | ITK, IKZF2, PBK | DRD3 4493/4885DRD2 4254/4885DRD4 4698/4885 |
| US-20230158157-A1 | POTENT AND SELECTIVE DEGRADERS OF ALK | ALK, ERBB2, PDGFRB | DRD3 3398/4885DRD2 2926/4885DRD4 3857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.